Trial Review

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT03577899




Registration number
NCT03577899
Ethics application status
Date submitted
13/06/2018
Date registered
5/07/2018
Date last updated
24/06/2021

Titles & IDs
Public title
Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1)
Scientific title
A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-Related Macular Degeneration (AMD) (PANDA-1)
Secondary ID [1] 0 0
KHB-1801
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Neovascular Age-related Macular Degeneration 0 0
Condition category
Condition code
Eye 0 0 0 0
Diseases / disorders of the eye

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Other interventions - 0.5 mg Conbercept Intravitreal Injection
Other interventions - 1.0 mg Conbercept Intravitreal Injection
Other interventions - 2.0 mg Aflibercept Intravitreal Injection

Experimental: 0.5 mg Conbercept - Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.

Experimental: 1.0 mg Conbercept - Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.

Active Comparator: Aflibercept - Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.


Other interventions: 0.5 mg Conbercept Intravitreal Injection
Subjects received 0.5 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (0.5 mg, q8w) for a total of 92 weeks treatment in the study eye.

Other interventions: 1.0 mg Conbercept Intravitreal Injection
Subjects received 1.0 mg conbercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every twelve weeks thereafter (1.0 mg, q12w) for a total of 92 weeks treatment in the study eye.

Other interventions: 2.0 mg Aflibercept Intravitreal Injection
Subjects received 2.0 mg aflibercept intravitreal injection at Day 1, Week 4 and Week 8 (three injection loading dose), and treated every eight weeks thereafter (2.0 mg, q8w) for a total of 92 weeks of treatment in the study eye.
Intervention code [1] 0 0
Other interventions
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Mean change from baseline in best corrected visual acuity (BCVA) at Week 36 in the study eye
Timepoint [1] 0 0
Baseline to Week 36
Secondary outcome [1] 0 0
Proportion of subjects maintaining vision (i.e., losing <15 ETDRS BCVA letters) from baseline to Week 36
Timepoint [1] 0 0
Baseline to Week 36
Secondary outcome [2] 0 0
Proportion of subjects gaining =15 ETDRS BCVA letters from baseline to Week 36
Timepoint [2] 0 0
Baseline to Week 36
Secondary outcome [3] 0 0
Mean change from baseline in central retinal thickness (µm) by spectral domain optical coherence tomography (SD-OCT) at Week 36
Timepoint [3] 0 0
Baseline and Week 36
Secondary outcome [4] 0 0
Proportion of subjects maintaining vision (i.e. losing <15 ETDRS BCVA letters) from baseline to Week 48
Timepoint [4] 0 0
Baseline to Week 48
Secondary outcome [5] 0 0
Mean change from baseline in ETDRS BCVA letter score at Week 96
Timepoint [5] 0 0
Baseline and Week 96
Secondary outcome [6] 0 0
Number of participants with adverse events as measure of safety and tolerability
Timepoint [6] 0 0
Baseline to Week 96
Secondary outcome [7] 0 0
Blood concentration of conbercept doses conducted in a subgroup of subjects, when feasible
Timepoint [7] 0 0
Baseline to Week 96
Secondary outcome [8] 0 0
Half-life (t1/2) of conbercept doses conducted in a subgroup of subjects, when feasible
Timepoint [8] 0 0
Baseline to Week 96
Secondary outcome [9] 0 0
Presence of anti-drug antibody of conbercept doses conducted in a subgroup of subjects, when feasible
Timepoint [9] 0 0
Baseline to Week 96

Eligibility
Key inclusion criteria
1. Men and women = 50 years of age at the Screening visit;

2. Females must be at least 1 year postmenopausal, or surgically sterilized, or, if of
childbearing potential, must have a negative pregnancy test at the Screening visit;

o Women of childbearing potential must agree to use a highly effective method of
contraception throughout the study.

3. Have received no previous treatment for neovascular AMD, including laser
photocoagulation and/or photodynamic therapy (PDT) and/or IVT VEGF antagonists
(treatment naïve) and;

4. Have active subfoveal choroidal neovascularization (CNV) lesions secondary to AMD
(including polypoidal choroidal vasculopathy (PCV)) evidenced by subfoveal fluorescein
angiography (FA) leakage, or definite subfoveal fluid by SD-OCT in the study eye at
Screening;

5. Have a ETDRS BCVA letter score of 78 to 25 in the study eye at Screening;

6. Are willing and able to sign the study written informed consent form (ICF).
Minimum age
50 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Have had any prior ocular or systemic treatment (investigational or approved) or
surgery for the treatment of neovascular AMD in the study eye except dietary
supplements or vitamins;

2. Have participated as a subject in any interventional clinical trial within one month
(30 days) prior to Baseline visit;

3. Have a subretinal hemorrhage that is either 50% or more of the total lesion area, or
blood is under the fovea and is one or more disc areas in size (greater than 2.5 mm2)
in the study eye at Screening;

4. Have any retinal pigment epithelial tears or rips in the study eye at Screening or
upon examination at Baseline;

5. Have any vitreous hemorrhage in the study eye upon examination at Baseline or history
of vitreous hemorrhage within eight weeks prior to Screening;

6. Have any other cause of CNV;

7. Have had prior pars plana vitrectomy in the study eye;

8. Have presence of a full thickness macular hole at Screening or upon examination at
Baseline or a history of a full thickness macular hole in the study eye;

9. Have prior trabeculectomy or other filtration surgery in the study eye;

10. Have uncontrolled glaucoma;

11. Have active intraocular inflammation in either eye at Screening or upon examination at
Baseline or a history of uveitis in either eye;

12. Have aphakia or pseudophakia with absence of posterior capsule (unless it occurred as
a result of yttrium aluminum garnet (YAG) posterior capsulotomy) in the study eye;

13. Significant media opacities, including cataract, in the study eye that, in the opinion
of the Investigator, could require either medical or surgical intervention during the
study period;

14. Have any use of long acting intraocular steroids, including implants, within six
months prior to Day 1, Baseline;

15. Have any known allergy to povidone iodine or known serious allergy to the fluorescein
sodium for injection in angiography;

16. Any history of known contraindications indicated in the Food and Drug Administration
(FDA)-approved label for the active control;

17. If female, be pregnant (positive urine pregnancy test at Screening) or breastfeeding.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Terminated
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
25/09/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
19/05/2021
Sample size
Target
Accrual to date
Final
1157
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Recruitment hospital [1] 0 0
Kanghong Investigative Site - Albury
Recruitment hospital [2] 0 0
Kanghong Investigative Site - Liverpool
Recruitment hospital [3] 0 0
Kanghong Investigative Site - Parramatta
Recruitment hospital [4] 0 0
Kanghong Investigative Site - Strathfield
Recruitment hospital [5] 0 0
Kanghong Investigative Site - Sydney
Recruitment hospital [6] 0 0
Kanghong Investigative Site - Adelaide
Recruitment hospital [7] 0 0
Kanghong Investigative Site - Glen Waverley
Recruitment hospital [8] 0 0
Kanghong Investigative Site - Melbourne
Recruitment hospital [9] 0 0
Kanghong Investigative Site - Crawley
Recruitment postcode(s) [1] 0 0
2640 - Albury
Recruitment postcode(s) [2] 0 0
2170 - Liverpool
Recruitment postcode(s) [3] 0 0
2150 - Parramatta
Recruitment postcode(s) [4] 0 0
2135 - Strathfield
Recruitment postcode(s) [5] 0 0
2000 - Sydney
Recruitment postcode(s) [6] 0 0
5000 - Adelaide
Recruitment postcode(s) [7] 0 0
3150 - Glen Waverley
Recruitment postcode(s) [8] 0 0
3002 - Melbourne
Recruitment postcode(s) [9] 0 0
6009 - Crawley
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Colorado
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Hawaii
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Kansas
Country [8] 0 0
United States of America
State/province [8] 0 0
Kentucky
Country [9] 0 0
United States of America
State/province [9] 0 0
Maryland
Country [10] 0 0
United States of America
State/province [10] 0 0
Massachusetts
Country [11] 0 0
United States of America
State/province [11] 0 0
Michigan
Country [12] 0 0
United States of America
State/province [12] 0 0
New Jersey
Country [13] 0 0
United States of America
State/province [13] 0 0
New York
Country [14] 0 0
United States of America
State/province [14] 0 0
Ohio
Country [15] 0 0
United States of America
State/province [15] 0 0
Oregon
Country [16] 0 0
United States of America
State/province [16] 0 0
Pennsylvania
Country [17] 0 0
United States of America
State/province [17] 0 0
Tennessee
Country [18] 0 0
United States of America
State/province [18] 0 0
Texas
Country [19] 0 0
United States of America
State/province [19] 0 0
Virginia
Country [20] 0 0
United States of America
State/province [20] 0 0
Washington
Country [21] 0 0
United States of America
State/province [21] 0 0
West Virginia
Country [22] 0 0
Argentina
State/province [22] 0 0
Buenos Aires
Country [23] 0 0
Argentina
State/province [23] 0 0
Cordoba
Country [24] 0 0
Argentina
State/province [24] 0 0
Santa Fe
Country [25] 0 0
Argentina
State/province [25] 0 0
Mendoza
Country [26] 0 0
Austria
State/province [26] 0 0
Hessen
Country [27] 0 0
Austria
State/province [27] 0 0
Klagenfurt am Wörthersee
Country [28] 0 0
Austria
State/province [28] 0 0
Linz
Country [29] 0 0
Austria
State/province [29] 0 0
Vienna
Country [30] 0 0
Belgium
State/province [30] 0 0
Laeken
Country [31] 0 0
Belgium
State/province [31] 0 0
Leuven
Country [32] 0 0
Canada
State/province [32] 0 0
Alberta
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Chile
State/province [36] 0 0
Region Metropolitana
Country [37] 0 0
Colombia
State/province [37] 0 0
Atlantico
Country [38] 0 0
Colombia
State/province [38] 0 0
Bogota
Country [39] 0 0
Colombia
State/province [39] 0 0
Cali
Country [40] 0 0
Colombia
State/province [40] 0 0
Medellin
Country [41] 0 0
Germany
State/province [41] 0 0
Bonn
Country [42] 0 0
Germany
State/province [42] 0 0
Darmstadt
Country [43] 0 0
Germany
State/province [43] 0 0
Düsseldorf
Country [44] 0 0
Germany
State/province [44] 0 0
Frankfurt am Main
Country [45] 0 0
Germany
State/province [45] 0 0
Freiburg
Country [46] 0 0
Germany
State/province [46] 0 0
Göttingen
Country [47] 0 0
Germany
State/province [47] 0 0
Hannover
Country [48] 0 0
Germany
State/province [48] 0 0
Heidelberg
Country [49] 0 0
Germany
State/province [49] 0 0
Homburg
Country [50] 0 0
Germany
State/province [50] 0 0
Köln
Country [51] 0 0
Germany
State/province [51] 0 0
Leipzig
Country [52] 0 0
Germany
State/province [52] 0 0
Ludwigshafen
Country [53] 0 0
Germany
State/province [53] 0 0
Mainz
Country [54] 0 0
Germany
State/province [54] 0 0
Marburg
Country [55] 0 0
Germany
State/province [55] 0 0
Muenster
Country [56] 0 0
Germany
State/province [56] 0 0
München
Country [57] 0 0
Germany
State/province [57] 0 0
Regensburg
Country [58] 0 0
Hong Kong
State/province [58] 0 0
Hong Kong
Country [59] 0 0
Lithuania
State/province [59] 0 0
Kaunas
Country [60] 0 0
Lithuania
State/province [60] 0 0
Vilnius
Country [61] 0 0
Mexico
State/province [61] 0 0
Guadalajara
Country [62] 0 0
Netherlands
State/province [62] 0 0
Zuid Holland
Country [63] 0 0
Netherlands
State/province [63] 0 0
Amsterdam
Country [64] 0 0
Netherlands
State/province [64] 0 0
Tilburg
Country [65] 0 0
New Zealand
State/province [65] 0 0
Auckland
Country [66] 0 0
Peru
State/province [66] 0 0
Lima
Country [67] 0 0
Philippines
State/province [67] 0 0
Manila
Country [68] 0 0
Poland
State/province [68] 0 0
Lesser
Country [69] 0 0
Poland
State/province [69] 0 0
Gdansk
Country [70] 0 0
Poland
State/province [70] 0 0
Lodz
Country [71] 0 0
Poland
State/province [71] 0 0
Lublin
Country [72] 0 0
Poland
State/province [72] 0 0
Olsztyn
Country [73] 0 0
Poland
State/province [73] 0 0
Wroclaw
Country [74] 0 0
Portugal
State/province [74] 0 0
Lisboa
Country [75] 0 0
Portugal
State/province [75] 0 0
Coimbra
Country [76] 0 0
Portugal
State/province [76] 0 0
Lisbon
Country [77] 0 0
Singapore
State/province [77] 0 0
Singapore
Country [78] 0 0
Spain
State/province [78] 0 0
Andalucia
Country [79] 0 0
Spain
State/province [79] 0 0
Cataluna
Country [80] 0 0
Spain
State/province [80] 0 0
Barcelona
Country [81] 0 0
Spain
State/province [81] 0 0
Bilbao
Country [82] 0 0
Spain
State/province [82] 0 0
Madrid
Country [83] 0 0
Spain
State/province [83] 0 0
Majadahonda
Country [84] 0 0
Spain
State/province [84] 0 0
Oviedo
Country [85] 0 0
Spain
State/province [85] 0 0
Pamplona
Country [86] 0 0
Spain
State/province [86] 0 0
Sant Cugat Del Vallès
Country [87] 0 0
Spain
State/province [87] 0 0
Santiago De Compostela
Country [88] 0 0
Spain
State/province [88] 0 0
Valencia
Country [89] 0 0
Spain
State/province [89] 0 0
Valladolid
Country [90] 0 0
Spain
State/province [90] 0 0
Zaragoza
Country [91] 0 0
Switzerland
State/province [91] 0 0
Canton De Vaud
Country [92] 0 0
Switzerland
State/province [92] 0 0
Bern
Country [93] 0 0
Switzerland
State/province [93] 0 0
Zürich
Country [94] 0 0
Taiwan
State/province [94] 0 0
Changhua City
Country [95] 0 0
Taiwan
State/province [95] 0 0
Taipei City
Country [96] 0 0
Taiwan
State/province [96] 0 0
Taipei city
Country [97] 0 0
Taiwan
State/province [97] 0 0
Taoyuan

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Chengdu Kanghong Biotech Co., Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this clinical study is to evaluate the efficacy and safety of two different
levels of conbercept intravitreal (IVT) injection as compared to the approved vascular
endothelial growth factor (VEGF) antagonist active control, aflibercept intravitreal
injection (2.0 mg/eye, Eylea®), in subjects with neovascular AMD.
Trial website
https://clinicaltrials.gov/ct2/show/NCT03577899
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Yan Cheng, MD, PhD
Address 0 0
Chengdu Kanghong Biotechnology Co.,Ltd.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT03577899